What You Should Know:
– HoloMD, the AI-powered Remote Therapeutic Monitoring (RTM) platform for psychiatry, announced the completion of a $1.6M first close of its $3M seed round.
– The new capital will accelerate the development and expansion of Dr. Holo™, the human-supervised AI companion designed to support psychiatrists and their patients between visits.
Scaling the AI Super-Companion, Dr. Holo™
Dr. Holo™, The AI-Powered Mental Health Superhero™, is built on 40 years of award-winning psychiatric expertise and helps providers deliver high-quality care between sessions. By providing daily engagement, evidence-based interactions, and actionable clinical insights, the platform is designed to improve patient outcomes and reduce clinician burnout.
- Engagement and Insight: Dr. Holo engages patients through daily check-ins and micro-interventions, then translates emotion, context, and behavior into concise, visit-ready insights for providers.
- Human Supervision: Crucially, each interaction is reviewed by licensed clinicians to ensure safety, empathy, and accuracy, balancing scalable automation with necessary human supervision—a model the company calls “science with soul”.
“Built by psychiatrists for psychiatrists and PMHNPs, our mission is to extend healing beyond the clinic walls,” said Bruce A. Kehr, MD, Founder & CEO of HoloMD. The platform equips clinicians with actionable insights to improve diagnosis and treatment while enabling reimbursable care between visits.
Validating the RTM Reimbursement Model
In just 15 months, HoloMD has moved from concept to live revenue and has successfully proven its RTM reimbursement model in the field. The platform structures patient interactions specifically for RTM CPT compliance, transforming previously unpaid work into work that is eligible for reimbursement across Medicare and commercial payers. HoloMD is now preparing to expand into additional practices and markets as it advances toward its full $3 million seed round closing.
